Medscape

Carboplatin De-Escalation Gains Ground in Early HER2+ Breast Cancer

New data confirm similar response rates with fewer toxicities when carboplatin is dropped from standard neoadjuvant therapy in early HER2-positive breast cancer.
ascopubs.org

Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer

Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ...
The New England Journal of Medicine

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive breast cancer subtype, and there remains an unmet need to improve outcomes in patients with previously untreated, programmed death ligand 1 ...
Cure Today

Enhertu Plus Perjeta Boosts Survival in HER2-Positive Breast Cancer

Enhertu plus Perjeta showed superior PFS compared to THP in HER2-positive advanced/metastatic breast cancer, irrespective of prior treatment, hormone receptor status, or PIK3CA mutations. Enhertu plus ...
ascopubs.org

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026) This trial adds to the ...